MK-1775

adavosertib · Merck KGaA

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-1775, covering 2017-05-03 to 2023-09-07. Get the full timeline:

Most recent: Clinical Trial Update: Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer [Phase 2]

See pricing